Ron A. A. Mathôt

TL;DR: High fecal concentrations of infliximab in the first days after therapy begins are associated with primary nonresponse, and additional studies are needed to determine how therapeutic antibodies are lost through the intestinal mucosa and how this process affects treatment response.

TL;DR: Addition of a conventional anti-diabetic dose of metformin does not improve outcome in patients with advanced pancreatic cancer treated with gemcitabine and erlotinib and future research should focus on patients with hyperinsulinaemia and patients with tumours showing markers of sensitivity to energetic stress.

TL;DR: It is concluded that the pharmacokinetics of MMF are comparable in Mrp2‐deficient rats receiving either CsA or Tac as co‐medication, and this finding suggests thatCsA‐mediated inhibition of the biliary excretion of MPAG by theMrp2 transporter is the mechanism responsible for the interaction between Cs a and MMF.

TL;DR: This study shows a significant relationship between the high within-patient variability in the clearance of tacrolimus, but not for MPA, and long-term graft failure.

TL;DR: Exposure to total MPA, as determined by MPA clearance, significantly increased with increasing renal function, albumin level, and hemoglobin as well as decreasing cyclosporine predose level, which provides an indication for therapeutic drug monitoring as MPA exposure may be altered.